Transdermal administration of buprenorphine
Patent 5069909 Issued on December 3, 1991. Estimated Expiration Date: 
June 20, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 20, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3433791 Trandermal delivery of opioids Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration Transdermal drug delivery using a dual permeation enhancer and method of performing the same Patent #: 4956171 InventorsAssigneeApplicationNo. 540908 filed on 06/20/1990US Classes:424/449, Transdermal or percutaneous424/448, Pressure sensitive adhesive means514/947Topical applicationExaminersPrimary: Page, Thurman K.Assistant: Phelan, D. Gabrielle Attorney, Agent or FirmForeign Patent References
International ClassA61F 013/00AbstractMethod and laminated composite for administering buprenorphine transdermally to treat pain. The composite comprises an impermeable backing layer and a reservoir layer containing buprenorphine and optionally a permeation enhancer combined with a pressure-sensitive adhesive with the amounts of buprenorphine and optional enhancer being sufficient to cause the buprenorphine to pass through the skin at a rate in excess of about 0.05 mcg/cm2 /hr.Other References
| |
